Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code：2666)

CONTINUING CONNECTED TRANSACTIONS REVISION OF THE ANNUAL CAPS UNDER THE 2024 MEDICAL RELATED PRODUCT PROCUREMENT FRAMEWORK AGREEMENT, 2024 MEDICAL SUPPLIES SALES FRAMEWORK AGREEMENT AND 2024 PROPERTY LEASE FRAMEWORK AGREEMENT

REVISION OF ANNUAL CAPS UNDER THE 2024 MEDICAL RELATED PRODUCT PROCUREMENT FRAMEWORK AGREEMENT

Reference is made to the announcement of the Company dated 23 November 2023 in relation to, among other things, the continuing connected transactions under the 2024 Medical Related Product Procurement Framework Agreement and the annual caps thereunder. On 23 November 2023, the Company and GT-PRC entered into the 2024 Medical Related Product Procurement Framework Agreement, pursuant to which, the Company and/or its subsidiaries will purchase medical related products and ancillary logistics and warehousing services from GT-PRC and/or its associates.

It is anticipated that the existing annual caps for the two years ending 31 December 2025 and 2026 would not be sufficient to meet the Company's growing demand in respect of the medical related products and ancillary logistics and warehousing services. Accordingly, on 28 October 2025, the Board resolved to revise the existing annual caps for the transactions under the 2024 Medical Related Product Procurement Framework Agreement for the two years ending 31 December 2025 and 2026. All terms and conditions under the 2024 Medical Related Product Procurement Framework Agreement remain the same.

REVISION OF ANNUAL CAP UNDER THE 2024 MEDICAL SUPPLIES SALES FRAMEWORK AGREEMENT

Reference is made to the announcement of the Company dated 23 November 2023 in relation to, among other things, the continuing connected transactions under the 2024 Medical Supplies Sales Framework Agreement and the annual caps thereunder. On 23 November 2023, the Company and GT-PRC entered into the 2024 Medical Supplies Sales Framework Agreement, pursuant to which, the Company and/or its subsidiaries will provide medical related products and ancillary logistics and warehousing services to GT-PRC and/or its associates.

It is anticipated that the existing annual cap for the year ending 31 December 2026 would not be sufficient to meet the growing demand in respect of the medical related products and ancillary logistics and warehousing services of GT-PRC. Accordingly, on 28 October 2025, the Board resolved to revise the existing annual cap for the transactions under the 2024 Medical Supplies Sales Framework Agreement for the year ending 31 December 2026. All terms and conditions under the 2024 Medical Supplies Sales Framework Agreement remain the same.

REVISION OF LEASE OF PROPERTY ANNUAL CAPS UNDER THE 2024 PROPERTY LEASE FRAMEWORK AGREEMENT

Reference is made to the announcement of the Company dated 23 November 2023 in relation to, among other things, the continuing connected transactions under the 2024 Property Lease Framework Agreement and the annual caps thereunder. On 23 November 2023, the Company and GT-PRC entered into the 2024 Property Lease Framework Agreement, pursuant to which, the Company and/or its subsidiaries shall lease properties from GT-PRC and/or its associates for office and warehousing purposes, and purchase miscellaneous property services accordingly.

It is anticipated that the existing lease of property annual caps for the two years ending 31 December 2025 and 2026 would not be sufficient to meet the Company's growing demand in respect of the lease properties for office and warehousing purposes. Accordingly, on 28 October 2025, the Board resolved to revise the existing lease of property annual caps for the transactions under the 2024 Property Lease Framework Agreement for the two years ending 31 December 2025 and 2026. All terms and conditions under the 2024 Property Lease Framework Agreement remain the same.

LISTING RULES IMPLICATIONS

As at the date of this announcement, GT-PRC directly and indirectly holds approximately 40.10% of the issued share capital of the Company and is a controlling shareholder of the Company. According to Rule 14A.07 of the Listing Rules, GT-PRC and its associates are connected persons of the Company.

Accordingly, the transactions between the Group and GT-PRC and/or its associates under the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios of the revised annual caps of each of the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement exceeds 0.1% but is less than 5%. Therefore, the transactions under the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement will constitute non-exempt continuing connected transactions of the Company subject to the reporting, annual review and announcement requirements but exempt from the Independent Shareholders' approval requirements pursuant to Chapter 14A of the Listing Rules.

As at the date of this announcement, among the Directors, Mr. Tong Chaoyin and Mr. Lin Chunhai hold positions in GT-PRC or its associates and accordingly they are considered to have material interests in the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement. Mr. Tong Chaoyin and Mr. Lin Chunhai had abstained from voting on the resolutions in respect of the revision of annual caps of 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement at the Board meeting. Save as disclosed above, no Director has interests in thetransactions under the 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement.

INTRODUCTION

Reference is made to the announcement (the "**Announcement**") of the Company dated 23 November 2023 in relation to, among other things, the continuing connected transactions under the 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement and the annual caps thereunder. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

It is anticipated that the existing annual caps of each of the 2024 Medical Related Product Procurement Framework Agreement and 2024 Property Lease Framework Agreement for the two years ending 31 December 2025 and 2026, and the existing annual cap of the 2024 Medical Supplies Sales Framework Agreement for the year ending 31 December 2026 would not be sufficient. Accordingly, on 28 October 2025, the Board resolved to revise the existing annual caps

for the transactions under each of the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement. All terms and conditions under each of the 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement remain the same.

THE 2024 MEDICAL RELATED PRODUCT PROCUREMENT FRAMEWORK AGREEMENT

The principal terms of the 2024 Medical Related Product Procurement Framework Agreement are set out as below:

Parties: GT-PRC and the Company

Major terms: The Company entered into the 2024 Medical Related Product Procurement Framework Agreement with GT-PRC on 23 November 2023, pursuant to which the Company and/or its subsidiaries will purchase medical related products and ancillary logistics and warehousing services from GT-PRC and/or its associates. All terms and conditions under the 2024 Medical Related Product Procurement Framework Agreement remain the same. The major terms of the 2024 Medical Related Product Procurement Framework Agreement are as follows:

- GT-PRC and/or its associates would sell various kinds of products and equipment, including but not limited to medical supplies such as pharmaceuticals and medical consumables, medical equipment and devices and provide ancillary logistics and warehousing services, to the Company and/or its subsidiaries;

- the Company and/or its subsidiaries and GT-PRC and/or its associates would enter into separate agreements which prescribe specific terms and conditions for the procurement of specific products and/or ancillary services, including purchase price, product model and specification, insurance and transportation arrangement and other terms; and

- the 2024 Medical Related Product Procurement Framework Agreement took effect from 1 January 2024 until 31 December 2026 and may be renewed by mutual consent.

Pricing policy: Purchase prices of relevant products and services provided by GT-PRC and/or its associates should be determined based on the production costs or trade costs (as the case may be) of the relevant products plus a premium determined through arm's length negotiation. Such prices should not be higher than: (i) government price (if appliable); (ii) comparable market price; and (iii) (if a comparable market price is not available) the production costs or trade costs (as the case may be) of the relevant products and services plus a premium determined through arm's length negotiation, in each case, having regard to the Company's internal control measures so as to ensure that terms are no less favorable to the Company than terms available to the Group offered by independent third parties.

EXISTING ANNUAL CAPS AND ACTUAL TRANSACTION AMOUNT

The existing annual caps for the three years ended/ending 31 December 2024, 2025 and 2026 were RMB266.00 million, RMB307.00 million and RMB328.00 million, respectively.

The following table sets out the actual amounts paid by the Group to GT-PRC and/or its associates pursuant to the 2024 Medical Related Product Procurement Framework Agreement:

	For the year ended 31 December 2024 *(RMB in millions)*	**For the nine months ended 30 September 2025** *(RMB in millions)*
The actual amounts paid by the Group to GT-PRC and/or its associates	249.29	215.67

As at the date of this announcement, the actual amounts incurred under the 2024 Medical Related Product Procurement Framework Agreement have not exceeded the existing annual cap for the year ending 31 December 2025.

THE REVISED ANNUAL CAPS

On 28 October 2025, the Board resolved to revise the existing annual caps for the transactions under the 2024 Medical Related Product Procurement Framework Agreement for the twoyears ending 31 December 2025 and 2026 as follows:

	For the year ending 31 December	
	2025 *(RMB in millions)*	**2026** *(RMB in millions)*
The amounts payable by the Group to GT-PRC and/or its associates	365.00	510.00

BASIS OF DETERMINATION OF THE REVISED ANNUAL CAPS

The above revised annual caps are based on the following factors:

(i) the existing annual caps for the two years ending 31 December 2025 and 2026 were RMB307.00 million and RMB328.00 million, respectively;

(ii) it is estimated that RMB22.00 million and RMB182.00 million in medical supplies procurement transactions will be increased in 2025 and 2026, respectively, in consideration of that, following Chongqing Pharmaceutical's integration into the GT-PRC, and in accordance with the Group's medical and pharmaceutical coordination initiatives, the Company has

continuously intensified efforts to advance the synergy between its pharmaceutical and medical businesses under the guidance of the principle of balancing the overall interests of both the Group and the listed company to achieve mutual benefits for all parties; and

(iii) it is estimated that the medical equipment procurement transactions will be increased by RMB36.00 million in 2025, taking into account that the Company proposes to acquire a tumor ultrasonic therapy equipment from Europe Temax, a subsidiary of GT-PRC, and collaborate with a hospital within the Hainan Boao Lecheng International Medical Tourism Pilot Zone (海南博鰲樂城國際醫療旅遊先行區) to launch the project.

REASONS FOR AND BENEFIT OF REVISING THE ANNUAL CAPS

The synergy strategy in medical and pharmaceutical will sustainably optimize collaboration, fully leverage the advantages of centralized procurement, steadily enhance the scale and efficiency of coordinated purchasing, and achieve deep integration between medical and pharmaceutical sectors while fostering mutual benefits for all parties.

The medical equipment procurement transactions will enable the Company to seize market opportunities and gain a first-mover advantage, accumulate practical experience for subsequent large-scale introduction of similar equipment, strengthen its competitive position in the high-end medical equipment sector, and enhance its brand influence in the healthcare market.

In view of the above reasons, the Directors (including the independent non-executive Directors, but excluding Mr. Tong Chaoyin and Mr. Lin Chunhai) are of the view that the revised annual caps for the transactions under the 2024 Medical Related Product Procurement Framework Agreement for the twoyears ending 31 December 2025 and 2026 have been arrived at (i) in the ordinary and usual course of the business of theCompany; (ii) on normal commercial terms; and (iii) on terms that are fair and reasonable and in the interest of the Company and its shareholders as a whole.

THE 2024 MEDICAL SUPPLIES SALES FRAMEWORK AGREEMENT

The principal terms of the 2024 Medical Supplies Sales Framework Agreement are set out as below:

Parties: GT-PRC and the Company

Major terms: The Company entered into the 2024 Medical Supplies Sales Framework Agreement with GT-PRC on 23 November 2023, pursuant to which the Company and/or its subsidiaries will provide medical related products and ancillary logistics and warehousing services to GT-PRC and/or its associates. The major terms of the 2024 Medical Supplies Sales Framework Agreement are as follows:

- the Company and/or its subsidiaries would provide medical related products and ancillary logistics and warehousing services to GT-PRC and/or its associates, including but not limited to medical consumables, pharmaceuticals, medical equipment and machinery equipment;

- the Company and/or its subsidiaries and GT-PRC and/or its associates would enter into separate agreements which prescribe specific terms and conditions for sales of specific products; and

- the 2024 Medical Supplies Sales Framework Agreement took into effect from 1 January 2024 until 31 December 2026 and may be renewed by mutual consent.

Pricing policy: The sales price that the Company charges GT-PRC and/or its associates should be determined based on the production costs or trade costs (as the case may be) of the relevant products plus a premium determined through arm's length negotiation. Such prices should not be higher than: (i) government price (if appliable); (ii) comparable market price; and (iii) (if a comparable market price is not available) the production costs or trade costs (as the case may be) of the relevant products plus a premium determined through arm's length negotiation, in each case, having regard to the Company's internal control measures so as to ensure that terms are no more favorable than terms offered by the Group to independent third parties.

EXISTING ANNUAL CAPS AND ACTUAL TRANSACTION AMOUNT

The existing annual caps for the three years ended/ending 31 December 2024, 2025 and 2026 were RMB29.00 million, RMB35.00 million and RMB40.50 million, respectively.

The following table sets out the actual amounts paid by GT-PRC and/or its associates to the Group pursuant to the 2024 Medical Supplies Sales Framework Agreement:

	For the year ended 31 December 2024 *(RMB in millions)*	**For the nine months ended 30 September 2025** *(RMB in millions)*
The actual amounts paid by GT-PRC and/or its associates to the Group	23.71	20.71

THE REVISED ANNUAL CAP

On 28 October 2025, the Board resolved to revise the existing annual cap for the transactions under the 2024 Medical Supplies Sales Framework Agreement for the year ending 31 December 2026 as follows:

	For the year ending 31 December 2026 *(RMB in millions)*
The amounts payable by GT-PRC and/or its associates to the Group	325.00

BASIS OF DETERMINATION OF THE REVISED ANNUAL CAP

The above revised annual cap is based on the following factors:

(i) the existing annual cap for the year ending 31 December 2026 was RMB40.50 million; and

(ii) it is estimated that the amounts of medical supplies transactions will be increased by RMB300.00 million in 2026 due to the deployment for supply chain integrated development of medical institutions in Shaanxi under the GT-PRC. The scope of integrated institutions encompasses 17 directly managed tertiary units (including 4 medical institutions) of the GT-PRC in Shaanxi. The supply chain management integration will adhere to the principles of "resource sharing, complementary strengths, and coordinated development", with "centralized procurement" as the core driver, which aims to establish a unified regional supply chain centralized procurement business management platform. As the centralized distribution unit for the Shaanxi region, Shaanxi Huahong Company intends to leverage GT-PRC's integrated development strategy in Shaanxi to provide pharmaceutical and medical consumables supply services to medical institutions under the GT-PRC within the region.

REASONS FOR AND BENEFIT OF REVISING THE ANNUAL CAP

The Group has abundant medical supplies resources and it has maintained a long-term cooperative relationship with GT-PRC and its associates. The Company's provision of pharmaceuticals and medical supplies to GT-PRC and/or its associates will benefit the Company by increasing its market share in Shaanxi and generating greater sales revenue.

In view of the above reasons, the Directors (including the independent non-executive Directors, but excluding Mr. Tong Chaoyin and Mr. Lin Chunhai) are of the view that the revised annual cap for the transactions under the 2024 Medical Supplies Sales Framework Agreement for the year ending 31 December 2026 has been arrived at (i) in the ordinary and usual course of the business of the Company; (ii) on normal commercial terms; and (iii) on terms that are fair and reasonable and in the interest of the Company and its shareholders as a whole.

THE 2024 PROPERTY LEASE FRAMEWORK AGREEMENT

The principal terms of the 2024 Property Lease Framework Agreement are set out as below:

Parties: GT-PRC and the Company

Major terms: The Company entered into the 2024 Property Lease Framework Agreement with GT-PRC on 23 November 2023, pursuant to which the Company and/or its subsidiaries shall lease properties from GT-PRC and/or its associates for office and warehousing purposes, and purchase miscellaneous property services accordingly. The major terms of the 2024 Property Lease Framework Agreement are as follows:

- with respect to the relevant leased properties, the Company and/or its subsidiaries and GT-PRC and/or its associates will enter into separate agreements which prescribe specific terms and conditions, including rental, payment method and other terms;

- the rental payable will be determined by the relevant parties through arm's length negotiation in accordance with the relevant PRC laws and regulations with reference to the prevailing market price; and

- the 2024 Property Lease Framework Agreement took into effect from 1 January 2024 until 31 December 2026 and may be renewed by mutual consent .

Pricing policy: The rental payable during the lease term should be determined by the relevant parties through arm's length negotiation with reference to the prevailing market price of local properties in proximity with a similar scale and quality and subject to the Company's internal control measures. The miscellaneous property service fees thereunder should not be higher than service fees of a similar type charged by independent third-party service providers.

EXISTING LEASE OF PROPERTY ANNUAL CAPS AND ACTUAL TRANSACTION AMOUNT UNDER THE PROPERTY LEASE FRAMEWORK AGREEMENT

The following table sets out the existing lease of property annual caps for the three years ended/ending 31 December 2024, 2025 and 2026:

	For the year ended/ending 31 December		
	2024	**2025**	**2026**
	(RMB in millions)	*(RMB in millions)*	*(RMB in millions)*
Lease of Property[(1)]	96.00[(2)]	17.00[(2)]	17.00[(2)]

Notes:

(1) In accordance with Hong Kong Financial Reporting Standard No. 16 "Leases", the basis of determination of the proposed annual caps for the three years ended/ending 31 December 2024, 2025 and 2026 have been determined with reference to the value of right-of-use assets relating to property lease at the commencement date of the property lease.

(2) The amount of the Lease of Property is the value of right-of-use assets relating to property lease at the commencement date of the property lease.

The following table sets out the rent amounts incurred under the lease of property of the 2024 Lease of Property Framework Agreement:

	For the year ended 31 December 2024 *(RMB in millions)*	**For the nine months ended 30 September 2025** *(RMB in millions)*
Lease of Property	56.44	7.83

As at the date of this announcement, the actual amounts incurred under the lease of property of the 2024 Property Lease Framework Agreement have not exceeded the existing annual cap for the year ending 31 December 2025.

THE REVISED LEASE OF PROPERTY ANNUAL CAPS

On 28 October 2025, the Board resolved to revise the existing lease of property annual caps for the transactions under the 2024 Property Lease Framework Agreement for the two years ending 31 December 2025 and 2026 as follows:

	For the year ending 31 December	
	2025 *(RMB in millions)*	**2026** *(RMB in millions)*
Lease of Property[(1)]	57.00[(2)]	237.00[(2)]

Notes:

(1) In accordance with Hong Kong Financial Reporting Standard No. 16 "Leases", the basis of determination of the proposed annual caps for the two years ending 31 December 2025 and 2026 have been determined with reference to the value of right-of-use assets relating to property lease at the commencement date of the property lease.

(2) The amount of the Lease of Property is the value of right-of-use assets relating to property lease at the commencement date of the property lease.

BASIS OF DETERMINATION OF THE REVISED ANNUAL CAPS

The above revised annual caps are based on the following factors:

(i) the existing lease of property annual caps for the two years ending 31 December 2025 and 2026 were RMB17.00 million and RMB17.00 million, respectively;

(ii) it is estimated that the amounts of the value of right-of-use assets of RMB40.00 million will be incurred in 2025 or 2026, as the Company proposes to enter into the Huanshikang Eye Hospital property lease agreement with GT-PRC in 2025 or 2026;

(iii) it is estimated that the amounts of the value of right-of-use assets of RMB150.00 million will be incurred in 2026, as the Company proposes to enter into the Beijing Zhongxing Hospital comprehensive building property lease agreement with GT-PRC in 2026; and

(iv) it is estimated that the amounts of the value of right-of-use assets of RMB30.00 million will be incurred in 2026, as the Company proposes to renewal Universal Times Square Phase II (通用時代中心二期) property lease agreement with GT-PRC in 2026.

REASONS FOR AND BENEFIT OF REVISING THE ANNUAL CAPS

Leasing the properties from GT-PRC and/or its associates will ensure the stable operations of the hospitals of the Company, especially accelerating the transition of Beijing Zhongxing Hospital from traditional to consumer-oriented healthcare models and break through development bottlenecks in the medical market. As compared to independent third parties, GT-PRC possesses a deeper understanding of the Company's requirements for office spaces and warehouse properties, thereby better supporting the Company's overall operations and development.

In view of the above reasons, the Directors (including the independent non-executive Directors, but excluding Mr. Tong Chaoyin and Mr. Lin Chunhai) are of the view that the revised annual caps for the lease of property transactions under the 2024 Property Lease Framework Agreement for the two years ending 31 December 2025 and 2026 have been arrived at (i) in the ordinary and usual course of the business of theCompany; (ii) on normal commercial terms; and (iii) on terms that are fair and reasonable and in the interest of the Company and its shareholders as a whole.

INTERNAL CONTROL MEASURES

For the continuing connected transactions under each of the 2024 Medical Related Product Procurement Framework Agreement and 2024 Property Lease Framework Agreement regarding purchasing products or services from GT-PRC and/or its associates,the Company has adopted the following internal procedures to safeguard the interest of the Shareholders as a whole:

(i) if a comparable market price is available, the Group should compare the proposed products price/service fee with the market price to ensure that the proposed prices/fees will not be higher than the price of product/service of a similar type or nature provided by independent third-party product/service providers;

(ii) before selecting an associate of GT-PRC as service provider, the Group should obtain price quotations from certain independent third-party product/service providers, and several rounds of assessment will be conducted by various internal departments, including the relevant business department, business operation department and treasury department. The factors to be considered by the Group in conducting internal assessments include price, quality, exclusivity of service, and value added to the Group;

(iii) if no comparable market price is available, the Group should conduct arm's length negotiation with the associate of GT-PRC to determine a reasonable profit margin based on the value of the relevant service and the actual costs and expenses incurred;

(iv) after arm's length negotiation with the associate of GT-PRC and rounds of internal assessment, the relevant internal department will report to the senior management of the Company who will approve separate transactions as appropriate;

(v) the treasury department of the Company will regularly collect and monitor the transaction amount of continuing connected transactions to ensure timely assessment on whether the relevant annual caps are exceeded; and

(vi) the independent non-executive Directors will also conduct annual review on the continuing connected transactions to ensure that such transactions have been entered into on normal commercial terms, are fair and reasonable and conducted according to the terms. The auditor of the Company will also conduct annual review on the pricing and annual cap of the continuing connected transactions.

For the continuing connected transactions under the 2024 Medical Supplies Sales Framework Agreement regarding supplying products or services to GT-PRC and/or its associates, the Company has adopted the following internal procedures to safeguard the interest of the Shareholders as a whole:

(i) the business departments of the Company will conduct market analysis on specific product or service, and make pricing proposal to the senior management after considering a number of factors, including overall market price, market share, orders and performance of major competitors, value added by relevant service and importance of customer relationship;

(ii) the business departments of the Company will conduct arm's length negotiation with the associate of GT-PRC, and after several rounds of internal assessment conducted on individual transactions based on the above factors by the Company's internal departments such as business operation department and treasury department, a final report will be made to the senior management who will approve individual transactions;

(iii) the business departments of the Company will also review the reasonableness of pricing for relevant products or services on regular basis according to the latest market intelligence, and report to the senior management, if necessary, for their approval of any adjustment;

(iv) the treasury department of the Company will regularly collect and monitor the transaction amount of continuing connected transactions; and

(v) the independent non-executive Directors will also conduct annual review on the continuing connected transactions to ensure that such transactions have been entered into on normal commercial terms, are fair and reasonable and conducted according to the terms. The auditor of the Company will also conduct annual review on the pricing and annual cap of the

continuing connected transactions.

IMFORMATION OF THE PARTIES

The Group

The Company is an integrated healthcare service provider with a focus on the fast-growing healthcare service industry in the PRC. Leveraging its own diversified healthcare resources and strong financial support, the Company has been committed to building up hospitals' comprehensive strengths in terms of healthcare technology, service quality, operating efficiency as well as managerial capacity.

GT-PRC

GT-PRC was established in March 1998 as a state-owned enterprise supervised by the State-owned Assets Supervision and Administration Commission. The principal business of GT-PRC comprises three major segments, namely, advanced manufacturing and technology service, pharmaceutical and healthcare and trade and engineering contracting.

LISTING RULES IMPLICATIONS

As at the date of this announcement, GT-PRC directly and indirectly holds approximately 40.10% of the issued share capital of the Company and is a controlling shareholder of the Company. According to Rule 14A.07 of the Listing Rules, GT-PRC and its associates are connected persons of the Company.

Accordingly, the transactions between the Group and GT-PRC and/or its associates under the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios of the revised annual caps of each of the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement exceeds 0.1% but is less than 5%. Therefore, the transactions under the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement will constitute non-exempt continuing connected transactions of the Company subject to the reporting, annual review and announcement requirements but exempt from the Independent Shareholders' approval requirements pursuant to Chapter 14A of the Listing Rules.

As at the date of this announcement, among the Directors, Mr. Tong Chaoyin and Mr. Lin Chunhai hold positions in GT-PRC or its associates and accordingly they are considered to have material interests in the 2024 Medical Related Product Procurement Framework Agreement, the 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement. Mr. Tong Chaoyin and Mr. Lin Chunhai had abstained from voting on the resolutions in respect of the revision of annual caps of 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease

Framework Agreement at the Board meeting. Save as disclosed above, no Director has interests in the transactions under the 2024 Medical Related Product Procurement Framework Agreement, 2024 Medical Supplies Sales Framework Agreement and 2024 Property Lease Framework Agreement.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

"2024 Medical Related Product Procurement Framework Agreement"	the medical related product procurement framework agreement entered into between theCompany and GT-PRC on 23 November 2023
"2024 Medical Supplies Sales Framework Agreement"	the medical supplies sales framework agreement entered into between theCompany and GT-PRC on 23 November 2023
"2024 Property Lease Framework Agreement"	the property lease framework agreement entered into between the Company and GT-PRC on 23 November 2023
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Beijing Zhongxing Hospital"	Beijing Zhongxing Hospital (北京中興醫院), a Grade I general hospital and a designated hospital for Beijing Basic Medical Insurance
"Board"	the board of Directors of the Company
"Chongqing Pharmaceutical"	Chongqing Pharmaceutical and Healthcare Industry Co., Ltd. (重慶醫藥健康產業有限公司), a company incorporated in the PRC with limited liability, a subsidiary of GT-PRC
"Company"	Genertec Universal Medical Group Company Limited (通用環球醫療集團有限公司), a company incorporated in Hong Kong with limited liability and the issued shares of which are listed on the main board of the Stock Exchange (stock code: 2666)
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"controlling shareholder"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the directors of the Company
"Europe Temax"	Genertec Europe Temax GmbH (通用技術歐洲德瑪斯有限公司), a subsidiary of GT-PRC

"Group"	the Company and its subsidiaries
"GT-PRC"	China General Technology (Group) Holding Company Limited (中國通用技術（集團）控股有限責任公司), a state-owned enterprise and a controlling shareholder of the Company
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Huanshikang Eye Hospital"	Huanshikang Eye Hospital (Beijing) Co., Ltd. (環視康眼科醫院（北京）有限公司), a company incorporated in the PRC with limited liability, a subsidiary of the Company
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"PRC" or "China"	the People's Republic of China
"RMB"	Renminbi, the lawful currency of the PRC
"Shaanxi Huahong Company"	Shaanxi Huahong Pharmaceutical Co., Ltd. (陝西華虹醫藥有限公司), which joined the Company in February 2017 and became a centrally-administered state-owned enterprise subsidiary under the Group
"Shareholders"	holder(s) of the shares of the Company
"Shares"	the ordinary share(s) in the capital of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary"	has the meaning ascribed to it under the Listing Rules
"%"	per cent

By order of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 28 October 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.